The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The company also reported significant progress toward its internally defined Sustainable Development Goals
The initiative is focused on a problem that continues to plague cancer outcomes in India
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Subscribe To Our Newsletter & Stay Updated
